Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Valérie Domergue"'
Autor:
Romain Brusini, Natalie Lan Linh Tran, Catherine Cailleau, Valérie Domergue, Valérie Nicolas, Flavio Dormont, Serge Calet, Caroline Cajot, Albin Jouran, Sinda Lepetre-Mouelhi, Julie Laloy, Patrick Couvreur, Mariana Varna
Publikováno v:
Pharmaceutics, Vol 15, Iss 7, p 1790 (2023)
Reperfusion injuries after a period of cardiac ischemia are known to lead to pathological modifications or even death. Among the different therapeutic options proposed, adenosine, a small molecule with platelet anti-aggregate and anti-inflammatory pr
Externí odkaz:
https://doaj.org/article/51b5c206bd4e446d9ced361c561529a2
Autor:
Indira Mendez-David, Céline Boursier, Valérie Domergue, Romain Colle, Bruno Falissard, Emmanuelle Corruble, Alain M. Gardier, Jean-Philippe Guilloux, Denis J. David
Publikováno v:
Frontiers in Cellular Neuroscience, Vol 11 (2017)
The incorporation of peripheral biomarkers in the treatment of major depressive disorders (MDD) could improve the efficiency of treatments and increase remission rate. Peripheral blood mononuclear cells (PBMCs) represent an attractive biological subs
Externí odkaz:
https://doaj.org/article/1fad19061d6647289403768e620d6988
Autor:
Jérôme Piquereau, Angèle Boet, Christine Péchoux, Fabrice Antigny, Mélanie Lambert, Mélanie Gressette, Benoît Ranchoux, Natalia Gambaryan, Valérie Domergue, Sharon Mumby, David Montani, Ian M. Adcock, Marc Humbert, Anne Garnier, Catherine Rucker-Martin, Frédéric Perros
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 7, p 1527 (2019)
The bromodomain and extra-terminal domain family inhibitors (BETi) are a promising new class of anticancer agents. Since numerous anticancer drugs have been correlated to cardiomyopathy, and since BETi can affect non-cancerous tissues, we aimed to in
Externí odkaz:
https://doaj.org/article/388049cbf6b341dcb90c0bbb8d6cc83d
Autor:
Varna, Romain Brusini, Natalie Lan Linh Tran, Catherine Cailleau, Valérie Domergue, Valérie Nicolas, Flavio Dormont, Serge Calet, Caroline Cajot, Albin Jouran, Sinda Lepetre-Mouelhi, Julie Laloy, Patrick Couvreur, Mariana
Publikováno v:
Pharmaceutics; Volume 15; Issue 7; Pages: 1790
Reperfusion injuries after a period of cardiac ischemia are known to lead to pathological modifications or even death. Among the different therapeutic options proposed, adenosine, a small molecule with platelet anti-aggregate and anti-inflammatory pr
Autor:
Mélanie Gressette, Kaveen Bedouet, Jean-Christophe Deschemin, Valérie Domergue, Florence Lefebvre, Arnaud Bruneel, Sophie Vaulont, Mathias Mericskay, Cecile Bouton, Anne Garnier
Publikováno v:
Archives of Cardiovascular Diseases Supplements. 15:205
Autor:
Corinne Buisson, Alexandre Marchand, Cynthia Mongongu, Magnus Ericsson, Valérie Domergue, François Coudoré
Publikováno v:
Drug Testing and Analysis. 13:1256-1269
Insulin-like growth factor-I (IGF-I) and its analogs LongR3 -IGF-I, Des(1-3)-IGF-I, and R3 -IGF-I are prohibited substances in sport. Although they were never approved for use in humans, they are readily available as black market products for bodybui
Autor:
Liting Wang, Fabien Hubert, Sarah Idres, Milia Belacel-Ouari, Valérie Domergue, Séverine Domenichini, Florence Lefebvre, Delphine Mika, Rodolphe Fischmeister, Véronique Leblais, Boris Manoury
Publikováno v:
European Journal of Pharmacology. 944:175562
Autor:
Cynthia, Mongongu, François, Coudoré, Valérie, Domergue, Magnus, Ericsson, Corinne, Buisson, Alexandre, Marchand
Publikováno v:
Drug testing and analysisREFERENCES. 13(7)
Insulin-like growth factor-I (IGF-I) and its analogs LongR
Autor:
Rui Adão, Catherine Rucker-Martin, David Montani, P. Mendes-Ferreira, Mélanie Lambert, Valérie Domergue, Véronique Capuano, Rozenn Quarck, Maria-Rosa Ghigna, Frédéric Perros, Jean-Luc Vachiery, Hélène Leribeuz, Angèle Boet, Carmen Brás-Silva, Marc Humbert, Fabrice Antigny
Publikováno v:
Cardiovascular Research
Cardiovascular Research, 2021, 117 (12), pp.2474-2488. ⟨10.1093/cvr/cvab016⟩
Cardiovascular Research, 2021, 117 (12), pp.2474-2488. ⟨10.1093/cvr/cvab016⟩
Aims Pulmonary hypertension (PH) is a common complication of left heart disease (LHD, Group 2 PH) leading to right ventricular (RV) failure and death. Several loss-of-function (LOF) mutations in KCNK3 were identified in pulmonary arterial hypertensio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a241b92460cd4ef7709eedf91baf2bd8
https://lirias.kuleuven.be/handle/123456789/669103
https://lirias.kuleuven.be/handle/123456789/669103
Autor:
Aniella Abi-Gerges, Liliana R. V. Castro, Jérôme Leroy, Valérie Domergue, Grégoire Vandecasteele, Rodolphe Fischmeister
Publikováno v:
Journal of Molecular and Cellular Cardiology
Journal of Molecular and Cellular Cardiology, Elsevier, 2021, 150, pp.109-121. ⟨10.1016/j.yjmcc.2020.10.011⟩
Journal of Molecular and Cellular Cardiology, Elsevier, 2021, 150, pp.109-121. ⟨10.1016/j.yjmcc.2020.10.011⟩
International audience; Background In cardiomyocytes, phosphodiesterases (PDEs) type 3 and 4 are the predominant enzymes that degrade cAMP generated by β-adrenergic receptors (β-ARs), impacting notably the regulation of the L-type Ca2+ current (ICa